Medical Advocates
Abacavir/Lamivudine (Epzicom)
 
Main Page

New and Noteworthy 
FDA Approvals
 Journal Citations
Conference Citations






 
Abacavir Main Page Main New/Newsworthy   Home Page    
Last Updated:  June 17, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
June 2008
FDA Approvals
     
 

TRUVADA (tenofovir disoproxil/emtricitabine- fixed dose) and EPZICOM (abacavir sulfate
and  lamivudine-fixed dose) approved by US FDA on August 02, 2004
 August 02, 2004
News Release
Journal Abstracts, Papers, Commentaries
     
 
Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in
Antiretroviral-Naïve Patients: A 48-Week Pilot Study.
 Elion R, Dejesus E, Sension M,et al
HIV Clin Trials. 2008 May-June 1;9(3):152-163.
 Abstract
 
Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine,
or abacavir with lamivudine.
 Shlay JC, Sharma S, Peng G, et al
J Acquir Immune Defic Syndr. 2008 May 1;48(1):53-62.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Short-term Safety and Tolerability of a Once-Daily Fixed-Dose Abacavir-Lamivudine Combination
versus Twice-Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the
ALOHA Study.
 Cohen CJ, Kubota M, Brachman PS, et al 
Pharmacotherapy. 2008 Mar;28(3):314-322.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Recent Availability of Two Novel, Fixed Formulations of Antiretroviral Nucleoside Analogues:
A 12-Month Prospective, Open-Label Survey of Their Practical Use and Therapeutic Perspectives
in Antiretroviral-Naive and -Experienced Patients.
 Manfredi R, Calza L.
AIDS Patient Care STDS. 2008 Feb 21
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Abacavir/lamivudine combination in the treatment of HIV-1 infection: a review.
 Waters L, Moyle G.
Expert Opin Pharmacother. 2006 Dec;7(18):2571-2580.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with
abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced
HIV-1-infected patients (CAL30001 Study).
Lamarca A, Clumeck N, Plettenberg A, et al
 J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):598-606.
  Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
 Anderson AM, Bartlett JA. 
Expert Rev Anti Infect Ther. 2005 Dec;3(6):871-83
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Abacavir and Lamivudine Fixed-Dose Combination Tablet Once Daily Compared With Abacavir
and Lamivudine Twice Daily in HIV-Infected Patients Over 48 Weeks (ESS30008, SEAL).
 Sosa N, Hill-Zabala C, Dejesus E, et al 
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):422-427
 Abstract
 
Two-once-daily fixed-dose NRTI combinations for HIV.
[No authors listed]  
Med Lett Drugs Ther. 2005 Feb 28;47(1203):19-20
 Abstract

Abacavir plus Lamivudine: A Review of their Combined Use in the Management of HIV Infection.
 Dando TM, Scott LJ. 
Drugs. 2005;65(2):285-302
 Abstract

Abacavir Main Page Main New/Newsworthy   Home Page    

Abacavir/Fixed Dose Lamivudine (Epzicom)
Main Page